Please login to the form below

Not currently logged in
Email:
Password:

China recalls GSK antibiotic

Chinese authorities have recalled GlaxoSmithKline's antibiotic Augmentin after traces of a compound used to make plastics more flexible were found in the treatment's syrup form

Chinese authorities have recalled GlaxoSmithKline's (GSK) antibiotic Augmentin (amoxicillin and clavulanate potassium) after traces of a compound used to make plastics more flexible were found in the treatment's syrup form.

Test results have shown the plasticiser diisodecyl phthalate (DIDP) is present in the antibiotic, according to China's State Food and Drug Administration. DIDP is banned in the production of medicines.

GSK has been ordered to immediately suspend sales of the product, which is regularly used to treat infections in children.

As reported in the UK's Daily Telegraph, a GSK spokesperson said: "GSK is currently in discussion with a number of regulatory agencies in the Asia Pacific region, some of whom have also conducted tests."

"The amount of phthalates identified as present in Augmentin syrup samples tested is very low; some tests have found none and the highest level reported by the authorities is 88 parts per million. Even this highest result is significantly lower than the levels that the US and European authorities deem as presenting no risk to humans."

Taiwan and Hong Kong had previously demanded GSK recall Augmentin after it was found to contain DIPD.

21st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...